[HTML][HTML] A comprehensive overview of globally approved JAK inhibitors
Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …
Current and future status of JAK inhibitors
DP McLornan, JE Pope, J Gotlib, CN Harrison - The lancet, 2021 - thelancet.com
An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …
and activator of transcription (STAT) signalling in multiple disease states has led to an …
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Background The global prevalence of ulcerative colitis is increasing, and induction and
maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety …
maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety …
Neutrophils as emerging therapeutic targets
Neutrophils are the most abundant circulating leukocytes, being the first line of defence
against bacterial and fungal infections. However, neutrophils also contribute to tissue …
against bacterial and fungal infections. However, neutrophils also contribute to tissue …
Diagnosis and management of rheumatoid arthritis: a review
D Aletaha, JS Smolen - Jama, 2018 - jamanetwork.com
Importance Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to
severe joint damage and disability. Significant progress has been made over the past 2 …
severe joint damage and disability. Significant progress has been made over the past 2 …
Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double‐blind …
R Fleischmann, AL Pangan, IH Song… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the efficacy, including capacity for inhibition of radiographic
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo …
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo …
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …
Rheumatoid arthritis: advances in treatment strategies
P Prasad, S Verma, Surbhi, NK Ganguly… - Molecular and cellular …, 2023 - Springer
Rheumatoid arthritis (RA) is characterised by severe joint and bone damage due to
heightened autoimmune response at the articular sites. Worldwide annual incidence and …
heightened autoimmune response at the articular sites. Worldwide annual incidence and …
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19
W Luo, YX Li, LJ Jiang, Q Chen, T Wang… - Trends in pharmacological …, 2020 - cell.com
Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …